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T helper 17 (Th17) cells play a complex and controversial role in tumor immunity and have
been found to exhibit a fluctuating identity within the context of cancer.The recent, expand-
ing literature on these cells attests to their puzzling nature, either promoting or suppressing
tumor growth depending on the malignancy and course of therapeutic intervention inves-
tigated. This review addresses several newly appreciated factors that may help delineate
Th17 cells’ immunological properties in the context of cancer. Several reports suggest that
inflammatory signals induced in the tumor milieu regulate the functional fate and antitu-
mor activity of Th17 cells. Recent findings also point to significant alterations in Th17 cells
due to their interplay with regulatory T lymphocytes and cytotoxic CD8+ T cells within the
tumor microenvironment. Finally, an appreciation for the stem cell-like properties of Th17
cells that augment their persistence and activity emerges from recent reports.The impact
of these factors on Th17 cells’ antitumor efficacy and how these factors may be exploited
to improve cancer therapies will be discussed.
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INTRODUCTION
CD4+ T helper 17 (Th17) cells play dynamic roles in inflamma-
tion and tumor immunity. Although, the link between inflam-
mation and cancer has long been appreciated, researchers have
just begun to elucidate the intricate – and contradictory – ways
that Th17 cells insinuate themselves into this relationship. Inflam-
mation within tumor tissue regulates immune cells (including
Th17 cells) according to compelling evidence. The net effect
is to dissipate antitumor immunity and contribute to the sur-
vival of cancer cells, exacerbating tumor growth and metastasis.
Yet, inflammation in the presence of Th17 cells appears to ini-
tiate, maintain, and enhance protective antitumor immunity in
some cases. Context may be important as the type of inflam-
matory response and cancer may govern whether Th17 cells
display beneficial versus detrimental effects in tumor immunity.
It goes without saying that understanding this process could
have extraordinary clinical significance and has resulted in a
rapid advance of research on Th17 cells in the field of cancer
immunotherapy.
Herein, we highlight recent work that looks at tumor immu-
nity in terms of both basic and translational aspects of Th17 cell
biology. Th17 phenotype, function and their apparently mutable
immunological properties will be examined. We also review the
interplay between Th17 and other immune cells in malignant sites,
and the mutual enhancement in antitumor activity that results
from those interactions. Finally, we discuss the clinical relevance
of Th17 cells in cancer therapy from the perspective of these new
findings.
BASICS: T HELPER SUBSETS IN TUMOR IMMUNITY
CD4+ T cells, which are key regulators of the immune system,
differentiate into various T helper (Th) cell lineages with dis-
tinct biological functions (1, 2). Ultimately, CD4+ T cells’ ability
to exert their effector functions depends on this differentiation,
which arises only when professional antigen-presenting cells (e.g.,
dendritic cells) provide the immunological cues that prompt for-
mation of one of several Th subsets: Th1, Th2, Th9, Th17, Th22,
and FoxP3+ regulatory T (Treg) cells (Figure 1) (2–4). In 1989,
the first two subsets of Th cells were defined – interferon-γ (IFN-
γ)-producing Th1 cells that promote cell-mediated immunity and
interleukin-4 (IL-4)-producing Th2 cells that support humoral
immune responses (5). Despite their differences, both subsets
were found to enhance antitumor immunity by inducing cyto-
toxic CD8+ T cell (CTL) expansion (6, 7). Conversely, Treg cells
were found to suppress antitumor immunity by inhibiting CTLs
(8, 9). Although, Th1/Th2 and Treg cells play a yin and yang role
in immunity, subsequent studies found that these three lineages
alone could not fully account for the development of inflamma-
tory responses to self or tumor tissue (3, 10). A full 20 years elapsed
before the knowledge gap could begin to be filled by the discov-
ery of a third Th subset that secretes IL-17: Th17 cells (11). The
identification of these cells expanded the Th1/Th2 paradigm and
helped shed light on the regulatory aspects of immunity to self
and tumor tissue.
T helper 17 cells’ contributions to inflammation and autoim-
munity have been established without controversy, but their
role in tumor immunity remains hotly debated (12–14). Some
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FIGURE 1 | Differentiation of helperT cell subsets is determined by
cytokines. In the presence of interleukin-6 (IL-6), IL-21, and transforming
growth factor-beta (TGF-β), naïve CD4+ T cells differentiate into a Th17 cell
phenotype, which is characterized by the expression of transcription factors
retinoic acid receptor-related orphan receptor-γt (RORγt) and signal transducer
and activator of transcription 3 (STAT3). IL-1β and IL-23 cytokines can promote
and stabilize this phenotype during cell expansion. Once programed, these
cells secrete IL-17A, IL-17F, IL-21, and IL-22, which play a key role in enhancing
autoimmunity and host defense. Cytokines IL-12, IL-4, and TGF-β and
transcription factors T-bet, GATA3, and FoxP3 have been shown to regulate
Th1, Th2, and Treg cell development, respectively. These distinct subsets
regulate immune response to foreign, self, and tumor antigens.
reports show that Th17 cells eradicate tumors, while other reports
reveal that they promote tumor progression. A satisfying, all-
encompassing explanation for these conflicting results has not
been forthcoming. However, recent work has provided a clue:
Th17 form and function are uniquely sensitive to a host of fac-
tors, including the type of cancer (e.g., prostate versus pancre-
atic), the therapeutic approach (e.g., vaccine versus adoptive cell
transfer therapy) and the stimuli to which the cells are exposed
during activation (e.g., T cell receptor strength). Thus, under-
standing the cytokines and transcription factors that regulate Th17
cell responses in the tumor milieu will be critical for advancing
efficacious cancer therapies.
DIFFERENTIATION AND FUNCTION OF Th17 CELLS
T helper 17 cells represent a CD4+ lineage distinct from Th1,
Th2, and Treg cells and are characterized by a unique molecular
and functional signature (15). Naïve CD4+ T cells undergo dif-
ferentiation into specific Th subsets via specific cytokine signals
(Figure 1). Th17 cells develop from naïve CD4+ T cells in the
presence of TGF-β, IL-6, and IL-1β and are maintained long-term
in the presence of IL-21 and IL-23 (16). Th17 cells are character-
ized by their capacity to secrete IL-17A, IL-17F, IL-21 IL-22, and
CCL20 (17–19). Additionally, Th17 generation is controlled by the
master transcription factors retinoic acid-related orphan receptor
(ROR)γt, RORα, aryl hydrocarbon receptor (AHR), and interferon
regulatory factor 4 (IRF4) (20–24). Cytokines and transcription
factors produced by Th17 cells can have both beneficial and
pathogenic effects. These controversial findings are further com-
plicated by direct environmental effects on Th17 differentiation
and function.
Environmental factors, such as toxins and ultraviolet light, have
recently been reported to play a role in the survival and func-
tion of Th17 cells. As previously mentioned, the ligand-dependent
AHR transcription factor helps drive the differentiation of Th17
cells (25). Ligands to activate AHR include hydrocarbons, such as
dioxins, which are toxic chemical compounds (26). Studies have
shown that the binding of these toxins, as well as other dietary
compounds, to AHR results in its activation and can drive the
differentiation of Th17 cells (22). Specifically, ligation of dioxins
to AHR increases the production of IL-22, IL-17A, and IL-17F by
Th17 cells and can lead to exacerbated autoimmunity. In addi-
tion to environmental toxins, it has been reported that exposure
to ultraviolet light can also affect the Th17 milieu. Phototherapies
using UV light have shown success in the treatment of exacer-
bating skin diseases such as psoriasis and atopic dermatitis (27,
28). Extensive analysis by Furuhashi et al. revealed that psoria-
sis patients treated with UV therapy had reduced skin lesions in
coordination with decreased levels of Th17 cells. Furthermore,
responders and non-responders could be predicted based on the
expression of Th17 cells prior to treatment, with increased levels
favoring a poor response. Building on previous findings that UV
treatment reduces the levels of IL-17 and IL-22 in psoriasis patients
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(29), these findings indicate that Th17 cells can be regulated by the
environment. However, caution is warranted based on more pre-
vious findings that UV treatment is an effective local treatment,
but does not augment Th17 cytokines systemically (30). Collec-
tively, these studies show that both localized (i.e., cytokines) and
environmental (i.e., toxins and UV exposure) factors can affect
Th17 cells and their resulting autoimmune manifestations. Due
to the dual nature of Th17 cells in both cancer and autoimmune
disease, it’s important to identify the presence of these cells in
various diseases. In addition to the previously mentioned identifi-
cation markers, Th17 cells can also be delineated by the increased
presence of dipeptidyl peptidase IV, called CD26, on their cell
surface.
CD26 is a multifunctional ectoenzyme involved in multiple
facets of T cell activation and function (31). Interestingly, T cells
with the highest expression of CD26 secrete the greatest amount
of IL-17A, which is the hallmark cytokine of Th17 cells. In contrast
to Th17 cells, Treg cells express low levels of CD26 and high levels
of the ectonucleotidases CD39 and CD73 (32). Moreover, CD26
up-regulation correlates with disease activity in human autoim-
mune manifestations linked to the presence of pathogenic Th17
cells, such as rheumatoid arthritis (31) and diabetes (33). Elevated
CD26 expression – as well as high expression of the inducible cos-
timulator (ICOS), the IL-23 receptor (IL-23R), and chemokine
receptor 6 (CCR6) – distinguishes Th17 cells from other human
T cell subsets (34, 35). Furthermore, the authors reported that the
expression of extracellular CCR4, CCR6, and CXCR3 can be used
to identify human Th1, Th2, and Th17 cells in healthy and diseased
individuals. Indeed, the identification of CD4+ T cell subsets via
these various extracellular markers has helped investigators shed
light on developmental and/or functional relationships between
Th17 and other T cells subsets in cancer and infectious disease.
DISTINCTIVE FEATURES OF CLASSICAL AND
NON-CLASSICAL (Th17-DERIVED) Th1 CELLS
Although cell surface markers provide a way to identify Th17 cells
from other subsets, the recent finding that Th17 cells can convert
into the Th1 lineage (gain an ability to secrete IFN-γ and lose their
capacity to secrete IL-17) – a phenomenon referred to as “plastic-
ity” (36) – has complicated our ability to discriminate these cells in
the tumor-bearing host. Thus, the question of how to distinguish
non-classical Th1 cells (i.e., Th17s that have converted to Th1)
from classical Th1 cells arises. Recent work suggests that the sur-
face marker lectin-like receptor CD161 discerns these two subsets.
As shown in Figure 2A, Th17 precursors can be detected by CD161
in cord blood, as these cells do not yet express IL-17A at the mRNA
or protein level (37). Along with CD161, Th17 precursors express
IL-23R and CCR6. When exposed to IL-1β and IL-23, precursors
FIGURE 2 | Culture conditions drive the expression ofTh17 or
non-classicalTh1 cells. Cell surface receptors distinguish T helper
subsets. (A)Th17 precursors can be identified from peripheral blood by
the presence of lectin-like receptor CD161, chemokine receptor 6
(CCR6), and IL-23 receptor (IL-23R). In the presence of IL-1β and IL-23,
these precursors differentiate into mature Th17 cells capable of IL-17A
production and identified by the addition of CCR4 and IL-17 receptor E
to their surface repertoire. In the presence of IL-23, the Th17 phenotype
is maintained as seen with the preservation of all surface markers,
IL-17A and RORγt. When cultured with IL-12, however, mature Th17
cells adopt a divergent phenotype that has both Th1 and Th17-like
aspects. These cells, termed Th1/Th17 cells, express CXCR3 instead of
CCR4, produce both IFN-γ as well as IL-17A, and have a high expression
of RORγt with an intermediate expression of the Th1 transcription
factor, T-bet. In the continued presence of IL-12, Th1/Th17 cells can
adopt a Th1-like phenotype and are termed non-classical Th1 cells. As
shown, non-classical Th1 cells have an increased expression of T-bet,
decreased RORγt, and produce only IFN-γ. (B) Classical Th1 cells are
directly derived from naïve CD4+ T cells in the presence of IL-12 and
can be identified through the expression of CXCR3, IFN-γ, and T-bet.
www.frontiersin.org June 2014 | Volume 5 | Article 276 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bailey et al. Th17’s identity crisis in cancer
transition into mature Th17 cells with the ability to produce IL-
17A. Conversely, when Th17 cells encounter IL-12, they convert
to a Th17/Th1 phenotype that co-expresses RORγ, T-bet, CXCR3,
CCR6, CD161, and IL-23R. Continued IL-12 presence (or compa-
rable signals) converts Th17/Th1 cells into a Th1-like phenotype.
These ex-Th17 cells are known as non-classical Th1 cells due to
their sustained expression of CD161. In contrast, classical Th1 cells
do not arise from Th17 precursors and thus, do not express CD161.
Rather, classical Th1 cells manifest from naïve CD4+ T cells in the
presence of IL-12 (Figure 2B). Very recent work has also impli-
cated the transcription factors Runx1 or Runx3, in combination
with T-bet, to be crucial for the generation of IFN-γ-producing
Th17 cells (38). Indeed, additional investigations to determine the
impact of non-classical versus classical Th1 cells in tumor immu-
nity will be important in designing therapies for patients with
cancer.
DISTRIBUTION OF Th17 CELLS AND THEIR DIFFERENTIAL
IMPACT ON TUMOR IMMUNITY
While Th17 cells are abundant in the mucosal tissues and sup-
port gut-related homeostasis, few Th17 cells (~0.1%) reside in the
peripheral blood of healthy individuals or cancer patients (13, 39,
40). However, a significantly greater number of Th17 cells infil-
trate tumors, especially compared to the density of Th17 cells in
the adjacent, non-tumor tissue of patients. This heightened pres-
ence of Th17 cells in tumor tissue holds true for a vast range of
malignancies, implying that tumors themselves produce factors
that promote Th17 cell trafficking to the diseased site (41–59).
Gut microbes also produce factors that promote Th17-
mediated tumor growth. A commensal bacterium called entero-
toxigenic Bacteroides fragilis (ETBF) was recently reported to
induce Th17 cells and to play a role in promoting colon car-
cinogenesis (60). Moreover, Th17 cells were found to directly
promote tumor growth, as neutralization of IL-17 and IL-23R
reduced the number of tumors that developed in the distal colon
of mice. Recent studies from Wick et al. have shown that induc-
tion of the Th17 immune response by ETBF appears to hinge on
Stat3 activation in immune cells (61). Given this new finding, two
mechanisms can be targeted to reduce tumor growth by ETBF:
one, gut microbes can be therapeutically targeted with antibi-
otics and two, the long-term activation of Stat3 can be inhibited
to decrease a Th17 immune response. Interestingly, however, gut
microbes perturbed by lymphodepletion/chemotherapy, a phe-
nomenon called microbial translocation, improve adoptive CD8+
T cell immunotherapies for melanoma (62).Yet,how the induction
of Th17 cells by microbial translocation impacts cell-based thera-
pies for various cancers remains unknown and will be important
for creating future treatments.
The high frequency of Th17 cells that exist in tumors (47) per-
mits researchers to examine their capacity to either promote or
suppress tumor growth. However, such work has only added to
the confusion concerning Th17 cells in cancer. Pro-inflammatory
cytokines secreted by Th17 cells, such as IL-17A, impair immune
surveillance and promote tumor growth (63, 64). Conversely, Th17
cells have been reported to directly eradicate melanoma tumors
in mice to a greater extent than Th1 cells (65, 66). Those stud-
ies involved an adoptive T cell transfer (ACT) therapy approach,
which takes advantage of CD4+ T cells that express a TCR rec-
ognizing tyrosinase tumor antigen (65). Exploitation of the TCR
leads to rapid expansion of Th17 populations to large numbers
ex vivo for reinfusion into the autologous tumor-bearing hosts.
This approach parallels ACT trials in human patients and has
allowed investigators to examine how infused TCR-specific Th17
cells interact with other immune cells in the body. These interac-
tions may either enhance or impair treatment outcome and could
hold the key to understanding the Janus-faced effects of either pro-
or antitumor Th17 cells. The interactions of Th17 cells and host
immune cells will be discussed later in this review, but first a better
understanding of the controversial roles of Th17 cells in cancer is
discussed directly below.
YIN AND YANG OF INFLAMMATORY Th17 CELLS IN TUMOR
IMMUNITY
The suspected relationship between inflammation and cancer
began more than a century ago, but researchers today are still
unraveling the importance of this affiliation in tumor progression
(67–71). Depending on the type of cancer encountered, a number
of factors could alter the effect of Th17 cells on a malignancy’s
pathology, including: the source of the Th17 cells (arising natu-
rally via tumor growth or adoptively transferred following ex vivo
manipulation), the functional phenotype of the cells and/or expo-
sure to therapeutic interventions such as chemotherapy. Under-
standing how Th17 cells cause inflammation in the context of
these factors, as well as how these elements impact patient sur-
vival, is of considerable interest in the field of oncology. One thing
that remains clear is that the influence of Th17 cell accumulation
in tumors on cancer progression is controversial. Some small mea-
sure of consensus is arising from the controversy: Th17 cell subsets
can possess either regulatory or inflammatory properties depend-
ing on the stimuli they encounter. These divergent phenotypes
may explain why Th17 cells have potent antitumor properties in
some experimental regimens but actually foster tumor growth in
others.
One possible explanation for this controversial phenomenon
could be that different types of tumor tissue foster the generation
of Th17 cells with different phenotypes. The generation of Th17
cells with opposing phenotypes in response to different tumor
tissue milieus would satisfyingly resolve the experimental discrep-
ancies. Indeed, high frequency Th17 cell infiltration into the tumor
bed of patients with colon or pancreatic cancer strongly corre-
lates with poor prognosis (72, 73). Conversely, increased Th17 cell
numbers in ovarian tumors have been associated with improved
patient survival rates (74–78). How the tumor regulates down-
stream signaling pathways in Th17 cells might also impact their
fate, as Kim and coworkers found that natural versus induced Th17
cells are regulated differently by Akt and mTOR pathways (79).
Identification of the tumor-localized triggers that shape distinct
Th17 cell responses will be invaluable for progress in the can-
cer immunotherapy field. An obvious direction is to identify the
antigen-specificity of tumor-infiltrating Th17 cells. Very possibly,
the Th17 cells with different antigen-specificity might have dif-
ferent impacts on the clinical outcome of cancer. Despite the vast
number of unknowns, one obvious role of Th17 cells in tumor
progression is their contribution to local inflammation.
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Th17 CELL-MEDIATED INFLAMMATION IN CANCER
Inflammation has long been recognized as a mediator of tumor
progression in diseases such as colorectal (80), pancreatic (81,
82), and lung (83) cancer. This phenomenon is largely based on
the continuous cell proliferation and cytokine production occur-
ring at sites of inflammation. More recent studies have shown
that alternative factors, such as β-catenin, can further augment
local T cells to increase pro-inflammatory cytokine production.
Keerthivasan et al. showed that activation of the Wnt/β-catenin
signaling in both Th17 and Treg cells correlates with the progres-
sion of colitis and colon cancer (84). Not only did tumor growth
correlate with enhanced pro-inflammatory cytokines, but these
findings could be reversed in RORγ−/− mice. Given that Th17
cells are dependent on RORγ, this finding is important for elu-
cidating how these cells drive tumor progression. Furthermore,
protein levels of IL-1β, IL-21, and TGF-β have been found to be
up-regulated in patients with gastric cancer (85). Based on the role
of these cytokines in Th17 differentiation, the microenvironment
of these patients appears to be more conducive for Th17 cell expan-
sion. The subsequent growth and cytokine production (IFN-γ and
IL-17) from these cells drives further inflammation and cancer
cell growth. Although these cytokines can drive inflammation-
dependent tumor growth, they also play controversial roles in
cancer progression or regression as discussed below.
Th17 CELLS AND TUMOR-ASSOCIATED ANGIOGENESIS
Inflammatory Th17 cells and their associated cytokines (i.e., IL-
17A, IL-17F, IL-21, IL-22, etc.) mediate tumor growth in two
distinct ways – by driving angiogenesis and by suppressing anti-
tumor immunity (86). Among the cytokines secreted by Th17
cells, IL-17A is best known to induce angiogenesis in tumor
tissue. Angiogenesis facilitates tumor growth by providing the
malignancy with a migratory egress to healthy tissues in patients.
Interestingly, tumors transfected with IL-17A were found to grow
and vascularize more rapidly than wild-type tumors in mice. Con-
versely, genetic IL-17A ablation impaired the growth of tumors in
mice (87). Positive correlations between the density of tumor-
infiltrating Th17 cells and increased micro-vessels have been
reported in many human cancers. Further work by Chang et al.
has shown that the production of IL-17A by Th17 cells also results
in the recruitment of myeloid suppressor cells (88). Depletion
of IL-17A or myeloid suppressor cells resulted in tumor reduc-
tion in vivo. These findings provide an angiogenesis-independent
mechanism by which IL-17A promotes tumor growth. Collec-
tively, these data suggest that IL-17A-producing T cells promote
tumor progression via multiple mechanisms (13, 89, 90).
Yet, other cytokines secreted by Th17 cells (IL-17F, IL-21, and
IL-22) exhibit anti-angiogenic properties, convoluting the over-
all correlation between Th17 cell activity and tumor growth in
the context of angiogenesis (91–93). The conditions that prompt
Th17 cells to secrete one or more of these cytokines may regulate
angiogenesis. Moreover, the critical setting of the type of tumor
that Th17 cells encounter could have some bearing on the out-
come of their regulatory role. In light of the findings by Sallusto’s
group that different pathogens promote the generation of either
effector or regulatory Th17 cells (94), it is possible that different
types of cancers will induce Th17 cells that can either facilitate or
suppress angiogenesis by differentially regulating IL-17A, IL-17F,
IL-21, and IL-22 secretion in patients. For example, the heightened
production of IL-22 by Th17/Th22 cells in patients with pancre-
atic (95) or lung (96) cancer correlates with poor prognosis and
survival. On the contrary, IL-22 has been shown to mediate tumor
reduction in certain models of breast cancer (92). Unraveling the
regulatory patterns of Th17 cells may require a deeper investiga-
tion into the plethora of cytokines within the tumor milieu of a
variety of cancers.
IMMUNOSUPPRESSIVE PROPERTIES OF Th17 CELLS
Although Th17 cells eradicate tumors when transferred into mice,
they also function as regulatory cells with the capacity to sup-
press antitumor immunity (12). Two distinct mechanisms that
sustain their immunosuppressive nature have been identified. One,
Th17 cells are capable of converting into Treg cells (i.e., plasticity;
Figure 3) (97, 98); two, Th17 cells release immunosuppressive
adenosine upon TGF-β-dependent ectonucleotidase expression
(99) as illustrated in Figure 4 and described in detail below.
Th17–Treg PLASTICITY PROMOTES TUMOR SUPPRESSION
In contrast to classical Th1 cells, Treg and Th17 cells convert into
other lineages. Th17 cells may originate from Treg cells with differ-
entiation mediated by IL-1β interaction with Tregs expressing the
IL-1 receptor (IL-1R) (38, 100–102). Th17 cells can also undergo
lineage conversion into Tregs, indicating that plasticity is a two-
way street. Astoundingly, this cellular inter-conversion does not
have rigid binary outcomes: intermediate phenotypes that co-
express FoxP3 and RORγt may also arise (103). These hybrids
display immunosuppressive functions toward CD8+ T cells (104).
Hence, distinguishing this discrete population from bona fide sub-
sets will be critical for a clear elucidation of the regulation of tumor
immunity by Th17 cells.
TGF-β INDUCES Th17 CELLS TO EXPRESS ECTONUCLEOTIDASES
Cytokines TGF-β, IL-6, and IL-23 program naïve CD4+ T
cells toward a Th17 phenotype and have been reported to
enhance autoimmune manifestations, particularly autoimmune
encephalomyelitis (EAE) (105). To test the role of these cytokines
in EAE, Th17 cells were generated in the presence of TGF-β plus
IL-6 or IL-23. As expected, cell subsets from both cultures secreted
IL-17A, but interestingly, only IL-23-cultured cells induced patho-
logic lesions in EAE mice. The authors postulated that the combi-
nation of TGF-β and IL-6 imprints Th17 cells with an immuno-
suppressive phenotype. The finding that TGF-β/IL-6-cultured cells
produced IL-10 upon myelin antigen recognition supported this
idea, as IL-10 dampens immune responses to self-antigen.
Guided by the autoimmune results in EAE, Chalmin et al. pos-
tulated that Th17 cells programed with IL-23 (plus IL-1β and/or
IL-6) will eradicate tumors when transferred into mice, while those
programed with TGF-β and IL-6 will be less effective (Figure 4)
(99, 106). Mechanistic studies revealed that TGF-β/IL-6-cultured
Th17 cells co-express CD39 and CD73 ectonucleotidases on their
surface. Concomitant expression of these two enzymes transforms
ATP or ADP into immunosuppressive adenosine (99). These sig-
naling events impair the antitumor activity of Th17 cells. As seen
in Figure 4A, TGF-β and IL-6 induce CD39 and CD73 expression
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FIGURE 3 | Cytokines determine the effector versus regulatory nature of
Th17 cells in tumor immunity. Cytokines and costimulatory molecules
distinctly transform Th17 cells into either an effector or regulatory phenotype,
which in turn regulates immunity to self/tumor tissue. (A) Effector Th17 cells
activated with IL-1β, IL-23, IL-6, IL-12 and/or ICOS agonist are poly-functional
and are capable of mediating potent antitumor immunity. (B) Regulatory Th17
cells programed with cytokines such as TGF-β, IL-2, and/or CTLA4 can dampen
their function and persistence, thereby potentially reducing their capacity to
kill tumors. Regulatory Th17 cells likely do not foster the induction or
cooperation of CTLs to the malignant site.
on Th17 cells by decreasing growth factor independent protein 1
(Gfi1) and activating STAT3,resulting in IL-17 and IL-10 secretion.
In contrast, Th17 cells programed with IL-1β, IL-6, and IL-
23 do not express CD39 or CD73 (Figure 4B). These cells co-
expressed T-bet and RORγt, resulting in secretion of IFN-γ and
IL-17, but not IL-10. Moreover, these Th17 cells mediated robust
tumor regression in mice, as reported by several labs (99, 107).
Thus, changes to the cytokines used in generating Th17 cells can
drastically impact the cell-mediated responses to tumors. While
the cytokines used to expand Th17 cells are instrumental for trans-
lational therapies, it is also clear that the generation of Th17 cells
with durable memory to tumors is even more critical, particularly
for gene-modified T cells for cancer. Fortunately, one consistent
finding has been the necessity of IL-23 for the maintenance of
Th17 cells.
Further work by Kuchroo’s group has shown that the signal-
ing induced by the interaction of IL-23 with IL-23R on Th17 cells
is crucial to obtain a pathogenic and sustained phenotype (108).
These authors discovered an essential downstream kinase, called
serum glucocorticoid kinase-1 (SGK1), which regulates IL-23R
expression on the cell surface. The addition of low levels of
TGF-β1 was sufficient to up-regulate IL-23R in Th17 cells and
to subsequently sustain their differentiated phenotype. Further
studies revealed that this finding mechanistically hinged upon the
deactivation of Foxo1, which appears to function as a Th17 sup-
pressor, following IL-23R induction. Intriguingly, SGK1 regulates
salt homeostasis and is also able to up-regulate IL-23R following
an increase in salt concentration, which could partially explain
the rise in autoimmune diseases in today’s society. These findings
indicate that maintenance and pathogenicity of Th17 cells relies
heavily on the binding of IL-23 to IL-23R.
Additional studies of the IL-23R in Th17 cell maintenance
revealed a striking difference when cultured with the cytokines
TGF-β1 or TGF-β3. While these cytokines signal through the same
receptor in Th17 differentiation, the addition of TGF-β3 to the cell
culture resulted in an enhanced expression of Il22 and Il23r (109).
Furthermore, these cells were more pathogenic and induced severe
EAE in mice compared to those given TGF-β1. Experimentally,
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FIGURE 4 |TGF-β inducesTh17 cells to express ectonucleotidases
and release immunosuppressive adenosine. (A)Th17 cells programed
with TGF-β and IL-6 fail to secrete IFN-γ but do secrete IL-17A and IL-10.
These cells expressed nominal amounts of Gfi1 (growth factor
independent protein 1 – repressor of ectonucleotidase), resulting in CD39
and CD73 ectonucleotidase expression on their cell surface. CD39 and
CD73 convert ATP to immunosuppressive adenosine, thereby
contributing to the inhibition of antitumor immunity. (B) Conversely,
programing CD4+ T cells in the absence of TGF-β but presence of IL-1β,
IL-6 and IL-23 supports the generation of Th17 cells that secrete IL-17A and
express RORγt and STAT3. Moreover, these cells also express
transcription factor Tbx21 and co-secrete IL-17 and IFN-γ but not the
immunosuppressive cytokine IL-10. These inflammatory Th17 cells also
express increased Gfi1. It is also possible that they express CD26, which
facilitates the conversion of adenosine to inosine upon binding of
adenosine deaminase (ADA). These infused cells promote the activation
of CD8+ effector T cells and cooperate to mediate tumor regression in an
IFN-γ and IL-17A-dependent manner.
cytokines TGF-β, IL-6, IL-21, IL-23, and IL-1β have been used in
different combinations by a number of groups to generate Th17
cells. The ramification of these results is that these cytokines can-
not be used interchangeably to generate Th17 cells as they have
differential effects on the phenotype.
STEM CELL-LIKE MEMORY Th17 CELLS IN TUMOR IMMUNITY
Gene therapy enables researchers to engineer T cells with TCR or
chimeric antigen receptors (CAR) that recognize tumor antigen,
which has unlocked new ACT treatments of unprecedented effi-
cacy (110–112). Unfortunately, most clinical trials have not risen
to their therapeutic expectations, marred by the use of terminally
differentiated T cells (113). Thus, a need arises for the generation
of memory T cells. Th17 cells display durable persistence and the
ability to mount rapid recall responses to tumors (107). Yet, effec-
tive means of generating Th17 cells with memory are still unclear.
Whereas much of our understanding of memory has been gleaned
from studies of CD8+ T cells, recent advancements in defining the
features of memory CD4+ T cells have trickled into the literature.
CD4+ T cells differentiate into distinct subsets upon anti-
genic encounter, adding complexity to the issue of memory (114).
Further complicating the matter, Th17 plasticity in their late devel-
opmental programing permits them to acquire at least some Th1
or Treg-like features. This plasticity is likely due to the prevail-
ing cytokines and signaling strength that they receive during
recall (36). Th17 diversity poses unique challenges to conclusively
defining memory phenotype, which makes it difficult to discern
if the mechanisms that maintain hematopoietic stem cells (HSC)
self-renewal are functional in Th17 cells.
Murine Th17 cells were recently discovered to be long-lived, to
possess a high proliferative potential upon antigenic re-encounter
and to self-renew with enhanced poly-functionality in vivo com-
pared to their Th1 counterparts (Figure 5) (107). These data were
unexpected given that Th17 cells express extracellular markers of
terminally differentiated effector memory in vitro (e.g., low CD62L
and CCR7 levels; high CD44 levels). Yet, these cells were camou-
flaged as terminal cells in vitro; once infused, the cells resumed
CD62L and CCR7 expression, indicative of a less differentiated
phenotype. Several pathways expressed in memory T cells were
identified as operational in these cells. For example, Th17 cells
expressed Lef1 and Tcf7 (downstream genes in the Wnt/β-catenin
pathway) to a greater extent than Th1 cells. This pathway is critical
for the generation of HSCs and has been found in stem cell-like
CD8+ T cells (115). In vivo, Th17 cells not only gave rise to Th1-
like progeny, but also possessed a self-renewing capacity. Dual-
function was required for Th17 cell-mediated tumor destruction
because cells deficient in IFN-γ or IL-17A had impaired activity.
Thus, the short lifespan of in vitro Th17 cells proves deceptive.
Mirroring results from murine Th17 cells, human Th17 cells
display durable memory to antigen in a variety of diseases (116).
Specifically, human Th17 cells were studied in the pathological
microenvironments of graft-versus-host disease, ulcerative colitis,
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FIGURE 5 | Divergent potential for self-renewal and plasticity inT
cell subsets. Over time, the majority of CD4+ T cells differentiate into
terminally differentiated effectors that possess short-lived immune
responses to tumor antigen. However, a small proportion of these cells
will enter into a self-renewing pool, resulting in the generation of
long-lived memory T cells. Th17 cells appear to exist in a progenitor-like
stage (A; Th17 precursor) compared to Th1 or Th0 cells (B and C,
respectively). Th17 cells possess a number of uniquely exciting traits:
enhanced self-renewal, multi-functionality and rapid recall responses to
tumor antigen.
and cancers. The number of durable memory Th17 cells was
increased in the chronic phase of these diseases. When transferred
into xenograft models, human Th17 cells mediated antitumor
immunity and had a high capacity to persist in vivo. These cells
expressed a relatively specific gene signature that incorporated
abundant anti-apoptotic genes and were resistant to activation-
induced cell death due to high c-FLIP expression (117). Together,
these data indicate that human Th17 cells exhibit the hallmark
properties of memory T cells, genetically similar to those found
in HSCs. The Th17 pathways associated with memory response
thus present themselves as attractive targets for manipulation, as
controlled activation of these pathways may lead to therapeutic
advances. Furthermore, predicting how these cells will interact
with host immune cells is important for therapeutic efficacy and
is discussed directly below.
Th17/IMMUNE CELL INTERPLAY IN THE TUMOR
Th17-CD8 DYNAMICS
It has recently been discovered that Th17 cells increase the func-
tion and frequency of CD8+ T cells in the tumor. Specifically,
adoptively transferred Th17 cells have been reported to activate
endogenous CD8+ T cells in mice with melanoma, which was
crucial for the antitumor effect (66). These studies revealed that
Th17 cells promoted dendritic cell recruitment into the tumors,
thus inducing CTL expansion. Th17 cells also promoted CCL20
chemokine production by tumor tissues, thereby recruiting CD8+
T cells to the malignant site. More recent work by Munegowda
et al. has shown that Th17 cells can activate CD8+ T cells in the
tumor milieu in a variety of ways, utilizing both direct and indi-
rect mechanisms (118). First, Th17 cells can directly interact with
CD8+ T cells via the acquisition of major histocompatibility com-
plex/peptide (pMHCI) and is crucial for CD8+ T cell response.
Second, soluble factors released by Th17 cells, such as IL-2 but not
IL-17, aid in the activation of CD8+ T cells. Finally, Th17 cells that
have homed to the tumor – due to their vast chemokine expres-
sion – can stimulate tumor tissue to produce chemoattractants
(i.e., CCL20), which then recruit CTLs to the tumor (66).
A potential synergistic interaction between Th17 and CD8+
T cells emerges from these antitumor studies, but work from the
Antony lab suggests caution against overemphasizing this inter-
play. The authors reported that donor CD4+ T cells eradicate
tumors directly without the need for host CD8+ T or NK cells
(119). These contrasting results highlight the need for follow up
studies on the role of antitumor CD4+ T cells (as well as Th1
and Th17 cells) on host or infused CD8+ T cells. What remains
clear, however, is that Th17 cells – under the right conditions – can
mediate tumor regression in mice with melanoma. Interactions
between Th17 and CD8+ T cells may have certain consequences
for the treatment outcome; however, another important question,
with ramifications for the efficacy and persistence of these treat-
ments, concerns the proportion and effects of Th17 and Treg cells
on each other and on tumor regression.
Th17–Treg DYNAMICS
The influence of Tregs on Th17 cells remains incompletely eluci-
dated, though the potential role of Tregs in dampening antitumor
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responses is known. One particular focus on Th17–Treg interac-
tions in immunotherapy involves the effect of IL-2 – often admin-
istered to mice in ACT experiments to support the expansion of
infused Th17 cells. IL-2 signaling exerts significant, yet divergent,
regulatory effects on Th17 and Treg cells in the tumor (120). Thus,
IL-2 bolsters Th17 cells, which subsequently dampen host Tregs in
the tumor. These findings would suggest that infused Th17 cells
reduce the number of host Tregs. Subsequent abrogation of Treg
suppression of tumor immunity offers one explanation for why
the therapeutic outcome in these Th17-based ACT treated mice is
often curative.
Alternate explanations for conflicting data in the literature may
be preferred. For example, Treg cells require IL-2 to overcome
FoxP3-mediated apoptotic properties for their in vivo mainte-
nance (121) and out-compete other subsets (i.e., Th17) for the
molecule via a high affinity IL-2 receptor. Thus, it is conceivable
that Tregs impair Th17 engraftment by depriving them of IL-
2, a situation that would certainly hamper antitumor immunity.
On the other hand, given that high IL-2 concentrations impair
Th17 expansion and function, Treg cells may actually support the
engraftment and function of Th17 cells by functioning as an IL-
2 cytokine sink (122), as was reported by the McGeachy lab. If
so, host Treg depletion would impair the persistence of antitumor
Th17 cells.
Restifo and colleagues very recently reported a novel role of
the transcriptional repressor BACH2 in regulating Treg differen-
tiation and decreasing the effector function of Th1 and Th17 cells
(123). BACH2 is a known regulator of Blimp-1 in B cells required
for class switch recombination; however, its role in T cells was
unknown (124). When CD4+ T cells were programed toward an
inducible Treg subset (via IL-2 and TGF-β), wild-type cells con-
verted to FoxP3+ Treg cells while Bach2 KO cells differentiated into
effector T cells (Figure 6A). Since a balance between regulatory
and effector cells is needed to maintain homeostasis (Figure 6B),
BACH2 serves as a critical regulator of the immune system. Inter-
estingly, Bach2 deficient cells exhibited superior effector function
as they secreted heightened levels of IL-17, IFN-γ, or IL-13 when
programed toward a Th17, Th1, or Th2 phenotype, respectively
(123). The authors also found that BACH2 not only stabilizes
Treg formation, but also blocks the generation of effector T cells
(Figure 6C). Thus, manipulating BACH2 expression in T cells
could bolster vaccine or cell-based immunotherapies for cancer.
CANCER THERAPIES: EMPLOYING THE DUAL NATURE OF
Th17 CELLS
The number of T cell-based therapies available for cancer patients
has grown exponentially in recent years. As shown in this review,
the mere presence of Th17 cells does not correlate with a unified
prognosis and could result in increased or decreased tumor bur-
den. For patients tumors that are exacerbated by Th17 cells (i.e.,
pancreatic), an obvious therapeutic target is to reduce the number
of these cells in the tumor microenvironment. Very recent work
has shown that treating pancreatic tumor-bearing mice with cer-
tain compounds, such as Embelin (XIAP inhibitor), can alter the
tumor microenvironment by skewing CD4+ T cells away from
Th17 differentiation and toward a Th1 phenotype (125). Among
several changes seen in the tumor microenvironment following
FIGURE 6 | Bach2 inhibitsT-effector differentiation and stabilizesTregs.
Cytokines present in the environment regulate the phenotypic and
functional fate of T cells. The combination of IL-2 and TGF-β creates an
environment conducive for the generation of inducible Treg cells. (A)WT
cells differentiated into FoxP3+ Treg cells when cultured with these
cytokines, while Bach2 knockout cells converted into effector T cells. This
suggests that Bach2 is (B) an instrumental regulator of the immune system
through (C) inhibition of effector function and thereby, stabilization of Tregs.
Embelin administration, the levels of IL-6/STAT3 were signifi-
cantly decreased and resulted in a reduced population of Th17
cells. Overall, this helped reduce Th17-mediated inflammation
within the tumor and prevented further growth of the malignant
cells. Previous work by Chang et al. showed that the production of
IL-17 by Th17 cells in the mouse lung cancer model K-ras (G12D)
was sufficient to drive tumor growth through the recruitment of
myeloid suppressor cells (88). Upon inhibition of IL-17, the mice
exhibited tumor reduction that resulted from decreased tumor
cell proliferation and angiogenesis. Thus, the specific targeting
of Th17 cells or their related cytokines could be promising for
patients with enhanced Th17-based inflammation in the tumor
microenvironment.
On the contrary, clinical trials to boost specific T cell popula-
tions via ACT have shown great promise in treating cancer patients.
In these trials, lymphocytes [either tumor-infiltrating lymphocytes
(TIL) or gene-engineered PBL] are often expanded with high dose
IL-2 (6000 IU/ml) and soluble OKT3 (anti-CD3), or are expanded
with magnetic beads decorated with CD3 and CD28 agonists (126,
127). Intriguingly, work by Paulos and coworkers suggest that new
methods of expanding human T cells to a Th17 phenotype could be
promising for ACT therapy. This group discovered that activation
of human Th17 cells with CD3 and ICOS agonists enhanced their
activity when transferred into tumor-bearing mice compared to
those activated with CD28 (128). Despite these findings, Th17 cells
and ICOS ligation have yet to be exploited in the clinic (129). How-
ever, gene therapy now permits the opportunity to redirect Th17
cells (via TCR or CAR that recognize tumor antigen) for the poten-
tial treatment of a broader range of malignancies (130–135). This
approach could circumvent the use of inefficacious differentiated
T cells obtained from TIL (113, 136). Given the significant antitu-
mor response seen following the infusion of Th17 cells into mice
bearing certain cancers (i.e., melanoma), future work to translate
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and redirect these cells to eradicate tumor tissue in the clinic could
provide treatment options for a vast array of malignancies.
CONCLUSION
The discovery of Th17 cells has led to a plethora of studies tar-
geting these cells to augment the antitumor response in patients.
A number of basic findings have also advanced the cancer field
through characterization of Th17 cells as a distinct subset that
builds on the Th1/Th2 paradigm. As discussed herein, the role of
Th17 cells in tumor immunity remains ambiguous and appears
to be dependent upon several factors. Cytokines, costimulatory
molecules and cell–cell interactions all impact the role of Th17
cells in the tumor milieu. While Th17 cells from human or murine
tumors appear to favor the growth of a variety of malignancies
by promoting angiogenesis or suppressing tumor immunity, con-
vincing evidence demonstrates that adoptively transferred Th17
cells can mediate durable antitumor responses in mice with large
tumors. However, the exact nature of how Th17 cells affect the
course of tumor development remains poorly understood, in part
because antigen-specificity of tumor-associated Th17 cells has not
been defined in most cases.
Whether Th17 cells adopt a pro- or anti-tumorigenic role is
largely dependent on the stimulation encountered by the cells.
A better understanding of the signals that impact cell func-
tion and immunological fate could elucidate the driving force
behind the Th17 identity crisis and is of considerable interest to
the field of cancer therapy. Further studies on the manipulation
of Th17 cells via blockades or genetic engineering for adoptive
transfer are invaluable to the advancement of current therapies.
More thorough knowledge of the mechanisms driving the anti-
tumor response in these cells could lead to the development of
enhanced vaccine and T cell-based therapies for patients with
cancer.
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